C
0I5R
vs
S&P 500
S&P 500
Over the past 12 months, 0I5R has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +18% growth.
Stocks Performance
0I5R vs S&P 500
Performance Gap
0I5R vs S&P 500
Performance By Year
0I5R vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CytRx Corp
Glance View
CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. The company is headquartered in Los Angeles, California and currently employs 3 full-time employees. The firm is focused on the discovery, research and clinical development of anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The firm's Linker Activated Drug Release (LADR) technology platform is a discovery engine to create a pipeline of anti-cancer molecules that avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Its product candidate, Aldoxorubicin is a rationally engineered cytotoxic which delivers anti-cancer agent, doxorubicin, into the tumor is in late-stage clinical trials. Its other product candidate, Arimoclomol for Niemann Pick disease Type C (NPC) and Gaucher disease.
